Abstract
Biosimilars have the potential for cost savings and thus help increase access to treatment. The study aims to understand the physicians’ perception and usage of biosimilars in HER2+ breast cancer (BC) and changes in trends from pre-biosimilar (only innovator trastuzumab was available) to current biosimilar era in India.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
